<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02723344</url>
  </required_header>
  <id_info>
    <org_study_id>N2232-P</org_study_id>
    <nct_id>NCT02723344</nct_id>
  </id_info>
  <brief_title>Biological Signatures, Probiotic Among Those With mTBI and PTSD</brief_title>
  <official_title>Biological Signature and Safety of an Immunomodulatory Probiotic Intervention for Veterans With Co-Occurring Mild TBI and PTSD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exaggerated inflammation in the body and brain is thought to play a role in the vulnerability
      to and aggravation and perpetuation of adverse consequences among those with co-occurring
      mild TBI (mTBI) and post-traumatic stress disorder (PTSD). The proposed study begins the
      process of investigating the use of a natural immunoregulatory/anti-inflammatory probiotic to
      treat chronic symptoms associated with co-occurring mTBI and PTSD among Veterans. By looking
      at the impact of probiotic supplementation on biological signatures of increased
      inflammation, as reflected by the gut microbiota, gut permeability, and biomarkers of
      peripheral inflammation, this study may lead to the identification of a novel intervention
      for the treatment of symptoms associated with these frequently co-occurring conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      United States military Veterans from recent conflicts are coping with symptoms related to
      mild traumatic brain injury (mTBI), persistent post concussive (PPC) symptoms, and
      posttraumatic stress disorder (PTSD). Many Veterans are resistant to conventional health and
      mental health interventions (e.g., medication, psychotherapy), and often symptoms are not
      significantly improved by traditional treatments. Moreover, there are limited treatments for
      symptoms associated with both conditions, which frequently co-occur. Alternative treatment
      methods are needed. One potential common underlying feature of both mTBI and PTSD is
      exaggerated inflammation, both peripherally and in the central nervous system, which is
      thought to play an important role in the vulnerability to, aggravation of, and perpetuation
      of adverse consequences of these often co-occurring conditions. Therefore, a novel
      intervention strategy would be the use of immunoregulatory/anti-inflammatory probiotics to
      reduce inflammation. In this study, the investigators will investigate the effects of an
      immunoregulatory probiotic on both biological signatures of systemic inflammatory processes
      and proximal signatures of probiotic administration. Lactobacillus reuteri (L. reuteri), a
      commensal organism that colonizes the human gut mucosa, suppresses mucosal inflammation via
      inhibition of the production of proinflammatory cytokines, and is the probiotic of interest.
      Specific aims of the study are to determine the: 1) effects of L. reuteri on biological
      signatures of gut microbiota, gut permeability, systemic inflammation processes, and stress
      responses; 2) feasibility of L. reuteri supplementation; 3) acceptability of L. reuteri
      supplementation; and 4) tolerability and safety of L. reuteri supplementation. Project aims
      will be assessed using a longitudinal, double blind, randomized placebo-controlled design.
      Participants will be Veterans with PPC symptoms, PTSD, and evidence of elevated systemic
      inflammation (based on high baseline plasma C-reactive protein [CRP] concentrations). After
      initial evaluation procedures, 20 participants will be randomized to probiotic
      supplementation and 20 will be randomized to placebo supplementation. The proposed line of
      research addresses the Office of Rehabilitation Research and Development (RR&amp;D) Service's
      goal of identifying means of intervening to increase function among those with mTBI and
      co-occurring psychiatric conditions. Long-term, this study may lead to a paradigm shift in
      the manner by which the investigators target clinical symptoms associated with PPC and PTSD
      symptoms, by beginning the process of supporting a multitargeted, neuroprotective approach.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2016</start_date>
  <completion_date type="Actual">June 1, 2019</completion_date>
  <primary_completion_date type="Actual">May 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Biologic</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C-Reactive Protein Change</measure>
    <time_frame>Baseline and approximately 10 weeks</time_frame>
    <description>Inflammation - Biological Signature (Blood)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Necrosis Factor Change</measure>
    <time_frame>2 weeks and approximately 10 weeks</time_frame>
    <description>Inflammation - Biological Signature (Blood)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>Approximately 10 weeks</time_frame>
    <description>The VAS was administered during the Trier Social Stress Task (TSST). The VAS is self-reported stress response on a Likert scale (1-10). A higher score indicates greater perceived stress. In the TSST, participants are asked to give a 5-minute speech and perform a math task. The VAS was administered at the baseline of the TSST, after the Speech Task, and after the Math Task.</description>
  </other_outcome>
  <other_outcome>
    <measure>Interleukin 6 Change</measure>
    <time_frame>2 weeks and approximately 10 weeks</time_frame>
    <description>Inflammation - Biological Signature (Blood)</description>
  </other_outcome>
  <other_outcome>
    <measure>Interleukin 10 Change</measure>
    <time_frame>2 weeks and approximately 10 weeks</time_frame>
    <description>Inflammation - Biological Signature (Blood)</description>
  </other_outcome>
  <other_outcome>
    <measure>Intestinal Fatty Acid Binding Protein (IFABP) Change</measure>
    <time_frame>2 weeks and approximately 10 weeks</time_frame>
    <description>Gut Permeability (Blood) - IFABP, measured by ELISA</description>
  </other_outcome>
  <other_outcome>
    <measure>D-amino Acid Oxidase (DAO) Change</measure>
    <time_frame>2 weeks and approximately 10 weeks</time_frame>
    <description>Gut Permeability (Blood) - DAO, measured by ELISA</description>
  </other_outcome>
  <other_outcome>
    <measure>Generic Assessment of Side Effects-Probiotics (GASE-P)</measure>
    <time_frame>Time 1 (Baseline), Time 2 (2 weeks), and Time 3 (10 weeks)</time_frame>
    <description>This measure of tolerability consists of 36 symptom descriptions organized by body parts. Participants are asked to rate if these symptoms were either &quot;not present&quot;, &quot;mild&quot;, &quot;moderate&quot;, or &quot;severe&quot; in the past week related to supplementation. Total severity scores range 0-108. A higher severity score indicates more symptom severity. Total symptom scores range 0-36. A higher symptom score indicates more symptoms.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Mild Traumatic Brain Injury</condition>
  <condition>Post Traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>L. reuteri</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Commercially available L. reuteri (deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and referenced as DSM 17938; Gerber Soothe Colic Drops, 100 million CFU/5 drops; formerly known as L. reuteri ATCC 55730) will be used in the proposed study. L. reuteri (phylum Firmicutes) is a gram-positive anaerobic commensal bacteria found in the gut microbiome of humans. Independent testing of the viability of the commercial product will be conducted in our laboratories by diluting drops, plating on agar in triplicate, and anaerobic culturing at 37 oC. The commercial strain (DSM 17938) has been used to improve intestinal functions in infants and reduce symptoms of infantile colic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sunflower and medium chain triglyceride oils</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sunflower and medium chain triglyceride oils</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>of Lactobacillus reuteri (L. reuteri; DSM 17938)</intervention_name>
    <description>Commercially available L. reuteri (deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and referenced as DSM 17938; Gerber Soothe Colic Drops, 100 million CFU/5 drops; formerly known as L. reuteri ATCC 55730) will be used in the proposed study. L. reuteri (phylum Firmicutes) is a gram-positive anaerobic commensal bacteria found in the gut microbiome of humans. Independent testing of the viability of the commercial product will be conducted in our laboratories by diluting drops, plating on agar in triplicate, and anaerobic culturing at 37 oC. The commercial strain (DSM 17938) has been used to improve intestinal functions in infants and reduce symptoms of infantile colic.</description>
    <arm_group_label>L. reuteri</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sunflower and medium chain triglyceride oils</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Sunflower and medium chain triglyceride oils</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of at least one deployment in support of Operation Enduring Freedom
             (OEF)/Operation Iraqi Freedom (OIF)/Operation New Dawn (OND)

          -  History of mTBI per the Ohio State University (OSU) TBI-ID85 with any endorsement of
             post concussive symptoms (PCS) associated with an mTBI, which occurred at least 6
             months prior to the baseline assessment

          -  Current symptoms in 3 or more of the following ICD-10 Post Concussive Symptom86
             categories as measured by the Rivermead Post Concussive Symptom Questionnaire
             (RPCSQ87; score of 2 or greater per symptom to qualify):

               -  headache

               -  dizziness

               -  malaise

               -  fatigue

               -  noise intolerance

               -  irritability

               -  depression

               -  anxiety

               -  emotional lability

               -  subjective concentration

               -  memory

               -  intellectual difficulties

               -  and/or insomnia

          -  Current diagnosis of PTSD per the Clinician Administered PTSD Scale-5 (CAPS-5)88

          -  Medical clearance by study physicians to participate in the protocol

          -  Age between 18 and 50

          -  Ability to provide informed consent

          -  Willingness not to take probiotic supplements (pills, tablets, oils, etc.) other than
             the product provided in the clinical study until all study procedures are completed

          -  Willingness to provide blood, as well as stool samples

        Exclusion Criteria:

          -  Inability to adequately respond to questions regarding the informed consent procedure

          -  Currently involved in the criminal justice system as a prisoner or ward of the state

          -  Non-English speaking

          -  Current (past month) alcohol or substance abuse or dependence

          -  Lifetime history of bipolar disorder or psychosis or anxiety disorders (excluding
             PTSD)

          -  Current major depressive disorder (MDD)

          -  Consistent (e.g., 5x/week or greater) probiotic supplementation within the last month,
             including probiotic food products such as yogurt, as determined by phone screen
             interview and Probiotic Food Check List

          -  Receiving antibiotics within the last month; use of topical antibiotics or topical
             steroids on the face, scalp, or neck or on arms, forearms, or hands within the
             previous 7 days

          -  Receiving medications that interfere with gut motility (opiates, loperamide, stool
             softeners)

          -  Presence of central venous catheters (CVCs)

          -  Gastrointestinal (GI) barriers as identified by the 2-week run-in period as determined
             by the study team (e.g., daily GI discomfort with frequent diarrhea prior to
             supplementation)

          -  Participation in conflicting interventional research protocol

          -  Body mass index (BMI) greater than or equal to 35 or less than or equal to 18

          -  Vital signs outside of acceptable range, i.e., blood pressure &gt;160/100, oral
             temperature &gt;100 F, pulse &gt;100

          -  Use of any of the following drugs within the last 6 months:

               -  systemic antibiotics

               -  antifungals

               -  antivirals or antiparasitics (intravenous, intramuscular, or oral)

               -  oral

               -  intravenous

               -  intramuscular

               -  nasal or inhaled corticosteroids

               -  cytokines or cytokine inhibitors

               -  methotrexate or immunosuppressive cytotoxic agents

          -  Acute disease at the time of enrollment (defer sampling until subject recovers)

               -  Acute disease is defined as the presence of a moderate or severe illness with or
                  without fever

          -  Chronic, clinically significant (unresolved, requiring on-going medical management or
             medication) pulmonary, cardiovascular, gastrointestinal, hepatic or renal functional
             abnormality, as determined by medical history or physical examination other than
             irritable bowel syndrome (IBS)

          -  History of cancer except for squamous or basal cell carcinomas of the skin that have
             been medically managed by local excision

          -  Unstable dietary history as defined by major changes in diet during the previous
             month, where the subject has eliminated or significantly increased a major food group
             in the diet

          -  Positive test for human immunodeficiency virus (HIV), Hepatitis B virus, or Hepatitis
             C virus

          -  Any confirmed or suspected condition/state of immunosuppression or immunodeficiency
             (primary or acquired) including HIV infection

          -  Major surgery of the GI tract, with the exception of cholecystectomy and appendectomy,
             in the past five years. Any major bowel resection at any time

          -  Regular urinary incontinence necessitating use of incontinence protection garments

          -  Female who is pregnant or lactating

          -  Treatment for or suspicion of ever having had toxic shock syndrome

          -  Those receiving immunosuppressive drugs or treatment including antineoplastic therapy,
             post-transplantation immunosuppressive therapy, and/or radiation therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa A Brenner, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rocky Mountain Regional VA Medical Center, Aurora, CO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rocky Mountain Regional VA Medical Center, Aurora, CO</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mirecc.va.gov/visn19/research/recruitment/index.asp</url>
    <description>Click here for more information about this study: Biological Signature and Safety of an Immunomodulatory Probiotic Intervention for Veterans with Co-Occurring Mild TBI and PTSD</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 1, 2016</study_first_submitted>
  <study_first_submitted_qc>March 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2016</study_first_posted>
  <results_first_submitted>May 21, 2020</results_first_submitted>
  <results_first_submitted_qc>July 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 28, 2020</results_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTSD</keyword>
  <keyword>Mild TBI</keyword>
  <keyword>Probiotic</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Brain Concussion</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02723344/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Although 75 participants were consented and enrolled in the study, 31 participants met inclusion criteria and continued participation.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Allocated to Placebo</description>
        </group>
        <group group_id="P2">
          <title>L Reuteri</title>
          <description>Allocated to L reuteri</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Prior to randomization</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Sham Probiotic</description>
        </group>
        <group group_id="B2">
          <title>L Reuteri</title>
          <description>Probiotic</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.7" spread="6.2"/>
                    <measurement group_id="B2" value="37.9" spread="7.3"/>
                    <measurement group_id="B3" value="37.4" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>C-Reactive Protein Change</title>
        <description>Inflammation - Biological Signature (Blood)</description>
        <time_frame>Baseline and approximately 10 weeks</time_frame>
        <population>A sufficient amount of plasma was not available to run CRP on 1 participant in the placebo group and 2 participants in the L reuteri group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Allocated to Placebo</description>
          </group>
          <group group_id="O2">
            <title>L Reuteri</title>
            <description>Allocated to L reuteri</description>
          </group>
        </group_list>
        <measure>
          <title>C-Reactive Protein Change</title>
          <description>Inflammation - Biological Signature (Blood)</description>
          <population>A sufficient amount of plasma was not available to run CRP on 1 participant in the placebo group and 2 participants in the L reuteri group.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.113" spread="1.2"/>
                    <measurement group_id="O2" value="-0.625" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.056</p_value>
            <method>Wilcoxon-rank sum</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Necrosis Factor Change</title>
        <description>Inflammation - Biological Signature (Blood)</description>
        <time_frame>2 weeks and approximately 10 weeks</time_frame>
        <population>A sufficient amount of plasma was not available to run TNF on 1 participant in the placebo group and 3 participants in the L reuteri group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Allocated to Placebo</description>
          </group>
          <group group_id="O2">
            <title>L Reuteri</title>
            <description>Allocated to L reuteri</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Necrosis Factor Change</title>
          <description>Inflammation - Biological Signature (Blood)</description>
          <population>A sufficient amount of plasma was not available to run TNF on 1 participant in the placebo group and 3 participants in the L reuteri group.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="1.4"/>
                    <measurement group_id="O2" value="-2.1" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.26</p_value>
            <p_value_desc>Wilcoxon Rank-Sum</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Visual Analog Scale</title>
        <description>The VAS was administered during the Trier Social Stress Task (TSST). The VAS is self-reported stress response on a Likert scale (1-10). A higher score indicates greater perceived stress. In the TSST, participants are asked to give a 5-minute speech and perform a math task. The VAS was administered at the baseline of the TSST, after the Speech Task, and after the Math Task.</description>
        <time_frame>Approximately 10 weeks</time_frame>
        <population>VAS was administered at T3 therefore data was only available on participants who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Allocated to Placebo</description>
          </group>
          <group group_id="O2">
            <title>L Reuteri</title>
            <description>Allocated to L reuteri</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale</title>
          <description>The VAS was administered during the Trier Social Stress Task (TSST). The VAS is self-reported stress response on a Likert scale (1-10). A higher score indicates greater perceived stress. In the TSST, participants are asked to give a 5-minute speech and perform a math task. The VAS was administered at the baseline of the TSST, after the Speech Task, and after the Math Task.</description>
          <population>VAS was administered at T3 therefore data was only available on participants who completed the study.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TSST Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.13" lower_limit="2.77" upper_limit="5.50"/>
                    <measurement group_id="O2" value="5.38" lower_limit="3.85" upper_limit="6.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSST After Speech</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" lower_limit="4.04" upper_limit="6.54"/>
                    <measurement group_id="O2" value="6.25" lower_limit="4.87" upper_limit="7.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSST After Math</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.44" lower_limit="5.06" upper_limit="7.84"/>
                    <measurement group_id="O2" value="7.13" lower_limit="5.60" upper_limit="8.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Interleukin 6 Change</title>
        <description>Inflammation - Biological Signature (Blood)</description>
        <time_frame>2 weeks and approximately 10 weeks</time_frame>
        <population>A sufficient amount of plasma was not available to run IL6 on 1 participant in the placebo group and 3 participants in the L reuteri group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Allocated to Placebo</description>
          </group>
          <group group_id="O2">
            <title>L Reuteri</title>
            <description>Allocated to L reuteri</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin 6 Change</title>
          <description>Inflammation - Biological Signature (Blood)</description>
          <population>A sufficient amount of plasma was not available to run IL6 on 1 participant in the placebo group and 3 participants in the L reuteri group.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".22" spread="2.4"/>
                    <measurement group_id="O2" value="-.07" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.64</p_value>
            <method>Wilcoxon Rank-Sum</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Interleukin 10 Change</title>
        <description>Inflammation - Biological Signature (Blood)</description>
        <time_frame>2 weeks and approximately 10 weeks</time_frame>
        <population>A sufficient amount of plasma was not available to run IL10 on 1 participant in the placebo group and 2 participants in the L reuteri group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Allocated to Placebo</description>
          </group>
          <group group_id="O2">
            <title>L Reuteri</title>
            <description>Allocated to L reuteri</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin 10 Change</title>
          <description>Inflammation - Biological Signature (Blood)</description>
          <population>A sufficient amount of plasma was not available to run IL10 on 1 participant in the placebo group and 2 participants in the L reuteri group.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.85"/>
                    <measurement group_id="O2" value="-0.23" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Intestinal Fatty Acid Binding Protein (IFABP) Change</title>
        <description>Gut Permeability (Blood) - IFABP, measured by ELISA</description>
        <time_frame>2 weeks and approximately 10 weeks</time_frame>
        <population>A sufficient amount of plasma was not available to run IFABP on 3 participants in the placebo group and 2 participants in the L reuteri group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Allocated to Placebo</description>
          </group>
          <group group_id="O2">
            <title>L Reuteri</title>
            <description>Allocated to L reuteri</description>
          </group>
        </group_list>
        <measure>
          <title>Intestinal Fatty Acid Binding Protein (IFABP) Change</title>
          <description>Gut Permeability (Blood) - IFABP, measured by ELISA</description>
          <population>A sufficient amount of plasma was not available to run IFABP on 3 participants in the placebo group and 2 participants in the L reuteri group.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.45"/>
                    <measurement group_id="O2" value="-0.04" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>D-amino Acid Oxidase (DAO) Change</title>
        <description>Gut Permeability (Blood) - DAO, measured by ELISA</description>
        <time_frame>2 weeks and approximately 10 weeks</time_frame>
        <population>A sufficient amount of plasma was not available to run DAO on 5 participants in the placebo group and 4 participants in the L reuteri group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Allocated to Placebo</description>
          </group>
          <group group_id="O2">
            <title>L Reuteri</title>
            <description>Allocated to L reuteri</description>
          </group>
        </group_list>
        <measure>
          <title>D-amino Acid Oxidase (DAO) Change</title>
          <description>Gut Permeability (Blood) - DAO, measured by ELISA</description>
          <population>A sufficient amount of plasma was not available to run DAO on 5 participants in the placebo group and 4 participants in the L reuteri group.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.24"/>
                    <measurement group_id="O2" value="0.03" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Generic Assessment of Side Effects-Probiotics (GASE-P)</title>
        <description>This measure of tolerability consists of 36 symptom descriptions organized by body parts. Participants are asked to rate if these symptoms were either &quot;not present&quot;, &quot;mild&quot;, &quot;moderate&quot;, or &quot;severe&quot; in the past week related to supplementation. Total severity scores range 0-108. A higher severity score indicates more symptom severity. Total symptom scores range 0-36. A higher symptom score indicates more symptoms.</description>
        <time_frame>Time 1 (Baseline), Time 2 (2 weeks), and Time 3 (10 weeks)</time_frame>
        <population>2 participants in the L reuteri group were lost to follow at Time 2, and then 2 more participants were lost to follow at Time 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Allocated to Placebo</description>
          </group>
          <group group_id="O2">
            <title>L Reuteri</title>
            <description>Allocated to L reuteri</description>
          </group>
        </group_list>
        <measure>
          <title>Generic Assessment of Side Effects-Probiotics (GASE-P)</title>
          <description>This measure of tolerability consists of 36 symptom descriptions organized by body parts. Participants are asked to rate if these symptoms were either &quot;not present&quot;, &quot;mild&quot;, &quot;moderate&quot;, or &quot;severe&quot; in the past week related to supplementation. Total severity scores range 0-108. A higher severity score indicates more symptom severity. Total symptom scores range 0-36. A higher symptom score indicates more symptoms.</description>
          <population>2 participants in the L reuteri group were lost to follow at Time 2, and then 2 more participants were lost to follow at Time 3.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time 1 - Severity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" spread="13.9"/>
                    <measurement group_id="O2" value="28.1" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time 1 - Symptom Count</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="5.5"/>
                    <measurement group_id="O2" value="15.9" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time 2 - Severity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" spread="13.2"/>
                    <measurement group_id="O2" value="23.7" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time 2 - Symptom Count</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="6.4"/>
                    <measurement group_id="O2" value="15.6" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time 3 - Severity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="11.3"/>
                    <measurement group_id="O2" value="14.3" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time 3 - Symptom Count</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="4.5"/>
                    <measurement group_id="O2" value="9.8" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study competition, an average of 10 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Allocated to Placebo</description>
        </group>
        <group group_id="E2">
          <title>L Reuteri</title>
          <description>Allocated to L reuteri</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Lisa A Brenner</name_or_title>
      <organization>Eastern Colorado Health Care System, Rocky Mountain MIRECC</organization>
      <phone>720-723-6488</phone>
      <email>lisa.brenner@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

